Reduction of risk of obesity
US-9480670-B2 · Nov 1, 2016 · US
Synbiotic composition for preventing disorders
US11638729B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11638729-B2 |
| Application number | US-201916730538-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 30, 2019 |
| Priority date | Jun 30, 2017 |
| Publication date | May 2, 2023 |
| Grant date | May 2, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of reducing the risk of occurrence of hyperinsulinemia, insulin resistance and/or diabetes type 2 in a human subject above 5 years of age, comprising administering to the human subject when 0 to 36 months of age a nutritional composition, comprising Bifidobacterium breve and a mixture of galacto-oligosaccharides and fructooligosaccharides, wherein the nutritional composition is an infant formula or follow on formula or young child formula, wherein the human subject is at increased risk of developing hyperinsulinemia, insulin resistance and/or diabetes type 2 due to being an infant born from a mother suffering from diabetes type 2 or gestational diabetes and wherein the human subject consumes after infancy a Western Style Diet that is increased in fat and is increased in saturated fatty acids, with the fat providing more than 35% of the total calories of the diet, and with the saturated fatty acids providing more than 10% of the total calories of the diet and wherein administration of the composition decreases plasma glucose-dependent insulinotropic polypeptide (GIP). 2. The method according to claim 1 wherein the composition is administered to the human subject when 0 to 12 months of age. 3. The method according to claim 1 , wherein the risk of occurrence of hyperinsulinemia, insulin resistance and/or diabetes type 2 is reduced when the human subject is above 18 years of age. 4. The method according to claim 1 , wherein the Bifidobacterium breve is Bifidobacterium breve M-16V. 5. The method according to claim 1 , wherein the nutritional composition is an infant formula or follow on formula. 6. The method according to claim 1 , wherein the nutritional composition comprises 10 4 to 10 12 cfu Bifidobacterium breve per gram dry weight of the nutritional composition and 0.25 to 20 wt % of the mixture of galacto-oligosaccharides and fructooligosaccharides based on dry weight of the nutritional composition.
Assignees
Inventors
Classifications
Preservation of foods or foodstuffs, in general · CPC title
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters · CPC title
Bacteria or derivatives thereof, e.g. probiotics · CPC title
- A61K35/745Primary
Bifidobacteria · CPC title
Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11638729B2 cover?
- The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.
- Who is the assignee on this patent?
- Nutricia Nv
- What technology area does this patent fall under?
- Primary CPC classification A61K35/745. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).